latest blog entries
Loading...
Branding...
latest headlines for company on cafepharma
Seeking Alpha
Tue, 06/18/13 - 9:50 am
Yahoo
Fri, 06/14/13 - 10:27 am
Pharmalot
Wed, 06/12/13 - 12:40 pm
Pharmalot
Tue, 06/11/13 - 9:15 am
Seeking Alpha
Mon, 06/10/13 - 12:23 pm
Seeking Alpha
Thu, 06/06/13 - 11:46 am
Seeking Alpha
Thu, 06/06/13 - 10:07 am
tags: Bristol-Myers Squibb, Eli Lilly, Forest Labs, Merck, Pfizer
Seeking Alpha
Wed, 06/05/13 - 11:34 am
tags: AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, Lonza
Bloomberg
Mon, 06/03/13 - 10:27 am
TheStreet.com
Mon, 06/03/13 - 10:20 am
tags: ASCO, Bristol-Myers Squibb, lambrolizumab, melanoma, Merck, nivolumab
Motley Fool
Sat, 06/01/13 - 12:48 pm
CNBC
Fri, 05/31/13 - 12:31 pm
tags: and Merck, ASCO, Bristol-Myers Squibb, cancer, immunotherapy, Roche
Last 30 twitter posts
Latest Health Message Board Posts
... has made this early trial ancient history by now. Many of us have been cured with Sofosbuvir without Bristol Myers Squibb's daclatasvir. Bristol is using its own drugs along with peg-interferon and ribavirin in trials to create they own therapies for ...
Posted by:
nobodyone
at
2013-06-07 05:00:00
on
medhelp.org
... exist without us, the patients. So they are responsible to us to start with 'Gilead is more interested in money than who'? Bristol-Myers Squibb a global pharma company with more than 31 billion in assets and 28,000 employees? I don't think that got their ...
Posted by:
Anonymouse88
at
2013-04-16 05:00:00
on
medhelp.org
... For reasons that are almost certainly financial in nature, Gilead has refused to do further work on this drug combination with Bristol-Myers Squibb, so there will be no further study of the regimen. With no Phase III trials, that means that the daclatasvir ...
Posted by:
ActingBrandNew
at
2013-04-12 05:00:00
on
medhelp.org
... — daclatasvir is a Bristol-Myers-Squibb drug, while sofosbuvir is made by Gilead Sciences. For reasons that are almost certainly financial in nature, Gilead has refused to do further work on this drug combination with Bristol-Myers Squibb, so there will ...
Posted by:
stef2011
at
2013-04-08 05:00:00
on
medhelp.org
... information to individual patients to which they have never examined . If the site is legit it is being sponsored by Bristol Myers Squibb and the responses will likely be tainted by the manufacture ( potential conflict of interest ) . It's my guess the ...
Posted by:
A.Ziffle
at
2013-03-06 11:43:00
on
healingwell.com
... in virologic response compared to entecavir monotherapy," Lok said in a press release issued by entecavir manufacturer Bristol-Myers Squibb. "The BE-LOW study data confirmed the results of previous studies showing limited or no benefit of combination ...
Posted by:
StephenCastlecrag
at
2013-03-06 06:00:00
on
medhelp.org
... rate of decline seen in younger HBeAg-positive patients. Acknowledgement: This study was supported by an unrestricted grant from Bristol-Myers Squibb. Assigned speakers: Dr. Wai-Kay Seto, The University of Hong Kong, Queen Mary Hospital , Hong Kong , Hong ...
Posted by:
Quest5245
at
2013-03-04 06:00:00
on
medhelp.org
... sure its even still available? February 12, 2013 A U.S. court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ...
Posted by:
mdudley
at
2013-03-03 06:00:00
on
medhelp.org
Bristol-Myers Squibb has a patient assistance program for Abilify. They say to call them if you have Medicare part D. There are some discount cards out ...
Posted by:
HectorSF
at
2013-03-02 06:00:00
on
medhelp.org
... of Dec. 8, Foster City, California-based Gilead said today in a statement. Gilead is competing with drugmakers including Bristol-Myers Squibb Co. (BMY) and AbbVie Inc. (ABBV) to gain approval for oral hepatitis C treatments that don’t involve injections ...
Posted by:
HectorSF
at
2013-03-02 06:00:00
on
medhelp.org